Evidence map›Paper›PMID 41164343›Full record

ArticleRSC chemical biology2026

Programmable synthesis of alkaloidal frameworks integrating Michael acceptor generates covalent probes for targeting POLE3 in HBV replication.

Nobuto Kaneko, Misao Himeno, Yuhi Kobayashi, Ryo Tanifuji, Hiroki Kubota, Haruki Mizoguchi, Makoto Muroi, Takehiro Suzuki, Masaya Sugiyama, Naoshi Dohmae and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nobuto KanekoDepartment of Chemistry, Graduate School of Science, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Misao HimenoDepartment of Developmental Medical Sciences, Graduate School of Medicine, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Yuhi KobayashiDepartment of Chemistry, Graduate School of Science, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Ryo TanifujiDepartment of Chemistry, Graduate School of Science, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.ORCID https://orcid.org/0009-0001-9466-9084
Hiroki KubotaDepartment of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology 2-24-16 Nakacho Koganei Tokyo 184-8588 Japan.
Haruki MizoguchiGraduate School of Natural Science and Technology, Okayama University 3-1-1 Tsushimanaka Kita-ku Okayama 700-8530 Japan.ORCID https://orcid.org/0000-0002-2148-9699
Makoto MuroiCentre for Sustainable Resource Science RIKEN, 2-1 Hirosawa Wako Saitama 351-0198 Japan.
Takehiro SuzukiCentre for Sustainable Resource Science RIKEN, 2-1 Hirosawa Wako Saitama 351-0198 Japan.
Masaya SugiyamaDepartment of Viral Pathogenesis and Control, National Institute of Global Health and Medicine, Japan Institute for Health Security 1-7-1 Kohnodai Ichikawa City Chiba 272-8516 Japan.ORCID https://orcid.org/0000-0002-9084-7197
Naoshi DohmaeCentre for Sustainable Resource Science RIKEN, 2-1 Hirosawa Wako Saitama 351-0198 Japan.ORCID https://orcid.org/0000-0002-5242-9410
Hiroyuki OsadaCentre for Sustainable Resource Science RIKEN, 2-1 Hirosawa Wako Saitama 351-0198 Japan.ORCID https://orcid.org/0000-0002-3606-4925
Taketomo KidoLaboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo 1-1-1 Yayoi Bunkyo-ku Tokyo 113-0032 Japan.
Atsushi MiyajimaLaboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo 1-1-1 Yayoi Bunkyo-ku Tokyo 113-0032 Japan.
Hiroki OguriDepartment of Chemistry, Graduate School of Science, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.ORCID https://orcid.org/0000-0001-8007-1631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing need for effective HBV treatments and lead compounds with novel mechanisms prompted us to explore synthetic strategies for generating skeletally diverse alkaloidal Michael acceptors. Our approach uniquely embeds Michael acceptors directly within multicyclic alkaloid-inspired frameworks, exploiting the azepinoindole scaffold-a privileged structure in indole alkaloids. A single-step assembly between the versatile intermediate 13 with methyl propiolate 14 or its derivatives enabled the rapid and divergent synthesis of six alkaloidal Michael acceptors (15-20). This strategy facilitated systematic diversification of three-dimensional functional group arrangements and precise tuning of the electronic and steric properties of the embedded α,β-unsaturated carbonyl moieties. The optimal hit 15 inhibited hepatitis B surface antigen (HBsAg) production with an IC

Identifiers

PMID41164343
PMCPMC12560046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.